Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

8.56
-0.0500-0.58%
Post-market: 8.560.00000.00%16:15 EDT
Volume:184.67K
Turnover:1.59M
Market Cap:209.76M
PE:-0.72
High:8.95
Open:8.48
Low:8.38
Close:8.61
52wk High:45.00
52wk Low:8.38
Shares:24.50M
Float Shares:10.79M
Volume Ratio:1.45
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:0.90
PE(LYR):-0.53

Loading ...

B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target

MT Newswires Live
·
Jul 22

Lyell Immunopharma Initiated at Buy by B. Riley Securities

Dow Jones
·
Jul 22

Lyell Immunopharma initiated with a Buy at B. Riley

TIPRANKS
·
Jul 22

Innovative Cellular Therapeutics Holdings Reports Lyell Immunopharma Share Sale Worth $137

Reuters
·
Jul 21

Innovative Cellular Therapeutics Holdings Reports Lyell Immunopharma Common Share Disposal Worth $137.3

Reuters
·
Jul 18

Lyell Immunopharma Files for Secondary Offering of Common Shares

MT Newswires Live
·
Jul 14

Lyell Immunopharma files to sell 1.1M shares of common stock for holders

TIPRANKS
·
Jul 14

Lyell Immunopharma - to Offer up to 1.1 Mln Common Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Jul 14

Citizens biotech analyst holds an analyst/industry conference call

TIPRANKS
·
Jul 07

Abcellera Appoints Lyell CEO Lynn Seely to Board as Independent Director

Reuters
·
Jul 06

Citizens biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 03

Lyell Immunopharma to Join H.C. Wainwright Cell Therapy Virtual Conference Fireside Chat

Reuters
·
Jun 25

Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner

Reuters
·
Jun 19

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

TIPRANKS
·
Jun 16

Lyell Immunopharma shareholders approved auditor Ernst & Young for 2026 fiscal year

Reuters
·
Jun 16

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 15

BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma

Reuters
·
Jun 13

Lyell Immunopharma - Pinacle Pivotal Trial Data Update Expected H2 2026; Bla Submission Planned H2 2027

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - Ronde-Cel Treated Over 100 Patients in 2L and 3L+ Lbcl With 97% Manufacturing Success Rate

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients With Large B-Cell Lymphoma at European Hematology Association 2026 Congress

THOMSON REUTERS
·
Jun 13